RevMedica Inc

RevMedica Gains FDA Safer Technologies Program (STeP) Acceptance and Expands IP Portfolio

FDA Safer Technologies Program (STeP) Accepted: Championing Safer Surgical Stapling

RevMedica becomes the only Endo Stapling Platform accepted into FDA’s STeP. The Company also expands its intellectual property protection with 5 new patents.

MIDDLETOWN, CT: RevMedica™, Inc. is pleased to announce its Endo Stapling Platform has been accepted into the U.S. Food and Drug Administration’s (FDA’s) Safer Technologies Program (STeP). Acceptance into the FDA’s Safer Technologies Program is reserved for “medical devices that are reasonably expected to significantly improve the safety of currently available treatments.” The program is intended to expedite development, assessment, and regulatory review by means of interactive communication with the FDA as the program progresses.

“The STeP designation offers additional validation of the unique advantages of our stapling platform,” states Tom Wenchell, Chief Executive Officer, RevMedica. “This is the product of many years spent listening to surgeons describe their need for objective, real-time data currently lacking in today’s stapling devices. We are fortunate to have such an experienced team of surgical stapling experts on staff to make this product a reality.” Tom will be participating in a panel discussion at the SAGES[1] NBT Innovation Weekend on “My Favorite Unmet Surgical Need,” Saturday, January 25th, to highlight these advancements.

Also, RevMedica announced the expansion of its intellectual property portfolio through the issuance of 5 new U.S. Patents, bringing the total to 20 US and 5 foreign issued patents. “We continue to build a strong foundation to bolster our unique offering and will continue to protect these advancements in the U.S. and abroad,” concluded Tom.

For further information, please contact: Thomas Wenchell, Chief Executive Officer RevMedica, Inc. Email: Tom@RevMedica.com revmedica.com

About RevMedica
RevMedica, backed by Telegraph Hill Partners, is a pioneering medical technology company set to revolutionize the way surgeons approach soft tissue management. With a mission focused on optimizing clinical decision-making and elevating patient safety, RevMedica aims to achieve these objectives through the development of cost-effective, environmentally-friendly, surgical systems. RevMedica is passionate about delivering enabling technology, better clinical results and a more sustainable healthcare ecosystem. Learn more at revmedica.com

Share:

Comments

    Comments are closed

    Thomas Wenchell

    Chief Executive Officer and Co-Founder
    Thomas Wenchell, Co-Founder and CEO of RevMedica
    Tom co-founded RevMedica in 2017, with the vision to revolutionize surgical procedures.
     
    With over 30 years of experience in the medical device industry and a wealth of expertise in engineering and product development, Tom has established himself as a global leader in the field. He possesses over 100 issued patents, a testament to his innovative contributions to the industry. 
    Tom's accomplishments speak to his ability to navigate complex challenges and drive innovation in the medical device industry. At RevMedica, Tom leads the development of a novel, handheld robotic solution intended to optimize clinical decision-making and improve patient safety with a cost-effective and environmentally friendly surgical system.
     
    Under his leadership, RevMedica has amassed a robust patent portfolio, assembled a team of key advisers, and successfully demonstrated the feasibility of RevMedica’s core design. Tom’s visionary leadership extends beyond product development.
     
    He has played a pivotal role in shaping RevMedica's strategic direction, building a talented team, and securing funding to support the company's growth. His hands-on approach to every aspect of the business underscores his dedication to ensuring the success of RevMedica.